GlassScriptPhysician profile
James Joseph Caserio
NPI 1558320945
$11,940.79
in general payments reported to CMS, 2019-2025
43 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $1,517 · 2021: $2,174 · 2022: $1,837 · 2023: $2,005 · 2024: $1,520 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,105.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,068.79 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $773.09 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $768.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $667.40 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $662.30 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $640.48 | 2019-2025 | Rexulti |
| Novo Nordisk INC | $541.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $501.94 | 2019-2025 | |
| Amgen INC. | $493.54 | 2019-2025 | Otezla, Repatha, Prolia |
| Kowa Pharmaceuticals America, INC. | $437.29 | 2019-2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $428.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.40 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $408.79 | 2020-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.77 | 2019-2022 | |
| Radius Health, INC. | $289.14 | 2019-2025 | Tymlos |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Caserio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.